Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENMD-2076 in Advanced Triple-Negative Breast Cancer
CTR20150075Phase 2Active
- Sponsor
- American Intronics
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enmd-2076 in triple-negative breast cancer (TNBC), sponsored by American Intronics. Started May 2016; status: active.
02
Drugs
enmd-2076
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20150075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150075.